Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC

Boothbay Fund Management LLC raised its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 104.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 678,414 shares of the company’s stock after purchasing an additional 346,136 shares during the quarter. Boothbay Fund Management LLC owned 1.25% of Fulcrum Therapeutics worth $6,241,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of FULC. Cubist Systematic Strategies LLC acquired a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth about $164,000. Jane Street Group LLC boosted its stake in Fulcrum Therapeutics by 62.1% during the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock worth $339,000 after buying an additional 45,157 shares during the period. Los Angeles Capital Management LLC purchased a new position in Fulcrum Therapeutics during the second quarter worth about $93,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Fulcrum Therapeutics by 57.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock valued at $2,357,000 after acquiring an additional 124,798 shares during the last quarter. Finally, Bailard Inc. purchased a new stake in shares of Fulcrum Therapeutics in the 2nd quarter valued at approximately $185,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on FULC. HC Wainwright upped their price objective on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, December 8th. The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Stifel Nicolaus set a $25.00 price target on Fulcrum Therapeutics in a research note on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Finally, Truist Financial set a $17.00 price objective on Fulcrum Therapeutics in a research note on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Fulcrum Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Insider Transactions at Fulcrum Therapeutics

In other news, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the transaction, the director directly owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This represents a 3.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.00% of the stock is owned by company insiders.

Fulcrum Therapeutics Trading Up 0.3%

Shares of FULC opened at $7.65 on Monday. The firm has a market capitalization of $509.49 million, a price-to-earnings ratio of -6.48 and a beta of 3.23. The firm’s fifty day simple moving average is $9.83 and its 200-day simple moving average is $9.62. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). On average, analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.